Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27481258 | 0.88 | HPGDS (0.42) | CTSKCCR1ADAM17CASP1CASP3 | |
| SCHEMBL13753280 | 0.83 | MLYCD (0.55) | CTSKCCR1ADAM17CASP1CASP3 | |
| SCHEMBL27497061 | 0.83 | TAS1R3 (0.67) | CCR1ADAM17HDAC1HDAC2NPC1 | |
| SCHEMBL1607014 | 0.83 | CTSB (0.56) | CTSKMEN1KMT2ARAB9A | |
| SCHEMBL7462665 | 0.82 | HDAC3 (0.55) | PIN1HDAC3HDAC1HDAC2MEN1 | |
| SCHEMBL27509580 | 0.81 | CCR1 (0.59) | CCR1HDAC3HDAC1HDAC2TAS1R3 | |
| SCHEMBL7465041 | 0.80 | MMP2 (0.54) | CTSKADAM17HDAC3UTS2R | |
| SCHEMBL7463161 | 0.80 | TAS1R3 (0.66) | CTSKHDAC3HDAC1HDAC2NPC1 | |
| SCHEMBL7468967 | 0.80 | CTNNB1 (0.43) | TAS1R3TAS1R1 | |
| SCHEMBL7470459 | 0.80 | CHRNA7 (0.41) | CTSKTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1171870-C | Cysteine protease inhibitors | ʷ��˿�������ȳ�ķ����˾ | 2004-10-20 | — | — | CN | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| CN-1171870-C | Cysteine protease inhibitors | ʷ��˿�������ȳ�ķ����˾ | 2004-10-20 | — | — | CN | disclosed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | disclosed |
| CN-1255162-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | disclosed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | CTSK 22/4885CCR1 861/4885ADAM17 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.